Strong Alliance: BioMap and Xellar Biosystems Forge Strategic Partnership to Pioneer the 'AI + Organ-on-a-Chip' Paradigm in Life Sciences R&D

Recently, BioMap and Xellar Biosystems, two portfolio companies of Legend Capital, officially signed a strategic cooperation framework agreement.The two parties will combine BioMap’s capabilities in foundational large models for life sciences and AI R&D platforms with Xellar Biosystems’ expertise in organ-on-a-chip technology, high-content 3D imaging, and drug development experimental systems.Engage in deep collaboration centered on “AI + Organ-on-a-Chip” to jointly explore a closed-loop R&D system that transforms high-quality wet-lab data into large-model predictions and intelligent decision-making, thereby driving the development of innovative drugs toward greater intelligence and efficiency.

As foundational large models in the life sciences continue to evolve, AI is advancing from molecular and protein-level analysis toward a deeper understanding of cells, tissues, and complex biological systems. However, enhancing model capabilities requires greater support from high-quality, standardized biological data.

BioMap leverages its 268-billion-parameter foundational life science large model, xTrimo, as its technological backbone, possessing robust capabilities in learning and predicting life science principles. It achieves a closed-loop integration of computational predictions and experimental validation through its AI-driven discovery system, BioMap OS. Meanwhile, Xellar Biosystems relies on organ-on-a-chip technology, high-content 3D imaging, and AI-based phenotypic analysis to continuously generate multimodal drug response data.This collaboration will further integrate the capabilities of both parties in “AI computing” and “wet lab experiments,” exploring new intelligent models for drug discovery and development.

Co-establishment of a Joint Laboratory.The two parties will conduct joint research on organ-on-a-chip wet-lab data and foundational large models for life sciences, exploring applications such as phenotype prediction and drug response assessment, to promote the formation of a “wet-dry” closed loop of “experiment–model–validation.”

Jointly develop a virtual organ/virtual cell prediction platform.Both parties will explore the use of large models to predict drug molecule responses in different organ-on-a-chip models, gradually establishing an R&D model of "virtual screening first, followed by chip validation."

Jointly Build a High-Quality Multimodal Database.Both parties will continuously accumulate data on drug responses, high-content 3D imaging, and multi-omics, and through the continuous iteration of data and models, establish a data-driven R&D closed loop.

This strategic collaboration represents an exploration into the deeper integration of foundational large models for life sciences with organ-on-a-chip technology. Moving forward, both parties will continue to leverage their respective strengths to promote the deep integration of real-world biological data with AI predictive capabilities, thereby providing more efficient technical pathways for innovative drug discovery, as well as efficacy and safety evaluation.